A Rabbit Model for the Evaluation of Drugs for Treating the Chronic Phase of Botulism
Antitoxin, the only licensed drug therapy for botulism, neutralizes circulating botulinum neurotoxin (BoNT). However, antitoxin is no longer effective when a critical amount of BoNT has already entered its target nerve cells. The outcome is a chronic phase of botulism that is characterized by prolon...
Main Authors: | Amram Torgeman, Eran Diamant, Eyal Dor, Arieh Schwartz, Tzadok Baruchi, Alon Ben David, Ran Zichel |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Toxins |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6651/13/10/679 |
Similar Items
-
Studying the differential efficacy of postsymptom antitoxin treatment in type A versus type B botulism using a rabbit spirometry model
by: Amram Torgeman, et al.
Published: (2018-09-01) -
Small Molecule Receptor Binding Inhibitors with In Vivo Efficacy against Botulinum Neurotoxin Serotypes A and E
by: Alon Ben David, et al.
Published: (2021-08-01) -
Immunologic and Protective Properties of Subunit- vs. Whole Toxoid-Derived Anti-Botulinum Equine Antitoxin
by: Alon Ben David, et al.
Published: (2022-09-01) -
Role of Homologous Fc Fragment in the Potency and Efficacy of Anti‐Botulinum Antibody Preparations
by: Amram Torgeman, et al.
Published: (2017-05-01) -
Four Cases of Food-Borne Botulism in a Family
by: Fariba Keramat
Published: (2002-12-01)